R&D projects

Surfix is continuously expanding its portfolio of surface modification technologies. Thus, we collaborate with industrial and academic partners throughout the European Union in a number of (funded) R&D projects.


ScaleTIME aims to improve the scalability of the manufacturing process for injection molded microfluidic cartridges with advanced functionalities by increasing the mutual compatibility of the different steps. Technology partners Axxicon, Micronit and Surfix contribute to the project by sharing their technologies for designing, manufacturing and coating microfluidic cartridges. Enzyre is the application partner and is developing PoC tests in the field of blood clotting, based on chemiluminescent enzymatic assays.

Read more

BioCDx (Horizon 2020)

Surfix BV is proud to participate in the BIOCDx program launched in January 2017. Within the project, partners from four different countries - Greece, Germany, Switzerland and The Netherlands - work on the development of a miniaturized, ultra-sensitive and reliable Point-of-Care (PoC) device with a disposable microfluidic cartridge for the monitoring of cancer biomarkers. The developed PoC device will support the detection of primary tumors and metastases focusing on breast cancer, hormone-independent prostate cancer and melanoma.

To this end the consortium gathered expertise from the photonic, nano-biochemical, micro-fluidic and reader/packaging platform to develop a portable, desktop PoC device. Within the BIOCDx project Surfix BV will supply the nanocoatings necessary to immobilize the different biomarkerson the surface.



In Coat PoCKET, Surfix is collaborating with Micronit Microtechnologies to develop new enabling technologies for advanced microfluidic Point-of-care devices. The goal is to develop a demonstrator bioassay based on a plastic microfluidic chip with passive flow control. The assay chip will combine electrostatically actuated capillary valves (developed by Micronit) with patterned hydrophobic, hydrophilic and antifouling nanocoatings (developed by Surfix).


Multidetect (eurostars)

The development of on-farm diagnostic tests is important for the rapid control of pig disease outbreaks. The goal of the Multidetect consortium, consisting of four European SMEs, is to develop highly sensitive diagnostic assays for the detection of pig pathogens in body fluids by combining aptamer and antibody based detection. The role of Surfix is the development of nanocoatings for the immobilization of bioreceptors on substrates for assays based on lateral flow and microarray technologies.


BioMeander (EFRO/OP OOST)

BioMeander brings together four Dutch partners to develop an extremely sensitive optical biodetection platform. Besides improving the generic sensitivity of the platform, two concrete application examples (screening of candidate medicines and detection of influenza virus) will be elaborated. Surfix’s contribution to the project is the development of optimized nanocoatings for the immobilization of bioreceptors on the sensor platform.



The RAAK program aims to strengthen the link between the Dutch Universities of Applied Science (HBO) and innovative (SME) companies by initiating joint R&D projects. Surfix is participating in a number of RAAK projects in the fields of biosensing and organ-on-a-chip.